This activity is supported by an unrestricted educational grant from Celgene Corporation and Takeda Oncology

Risk Stratification in Multiple Myeloma

Angela Mayo, MS, PA-C
Mayo Clinic Scottsdale

Craig B. Reeder, MD
Mayo Clinic Scottsdale

New innovative therapies in MM have increased significantly over the past decade and have improved survival rates.  Options now include proteasome inhibitors, immunomodulatory agents, HDAC inhibitors, monoclonal antibodies as well as standard chemotherapy. This activity equips the AP with critical updates in NCCN guidelines, diagnosis, risk-stratification, and treatment options, including: mechanism of action, side effect profile and supportive care.


Download Podcast


Download Transcript


Download Slides


Download Slides & Transcripts


These CME/CE/CPE accredited activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.